Search details
1.
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Blood
; 141(17): 2114-2126, 2023 Apr 27.
Article
in English
| MEDLINE | ID: mdl-36720090
2.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Article
in English
| MEDLINE | ID: mdl-37633306
3.
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Invest New Drugs
; 40(4): 762-772, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35467243
4.
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
J Clin Oncol
; 41(5): 1105-1115, 2023 02 10.
Article
in English
| MEDLINE | ID: mdl-36288547
5.
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
JTO Clin Res Rep
; 3(1): 100262, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-35005654
6.
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
In Vivo
; 36(4): 1615-1627, 2022.
Article
in English
| MEDLINE | ID: mdl-35738590
7.
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Mol Cancer Ther
; 20(10): 1988-1995, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34315767
8.
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Clin Cancer Res
; 27(21): 5781-5792, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-34426443
9.
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
Mol Cancer Ther
; 19(5): 1210-1217, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32127466
10.
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
Cancer Res
; 66(11): 5858-66, 2006 Jun 01.
Article
in English
| MEDLINE | ID: mdl-16740725
11.
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
J Clin Oncol
; 36(33): 3298-3306, 2018 11 20.
Article
in English
| MEDLINE | ID: mdl-30285518
12.
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 23(19): 5981-5992, 2017 Oct 01.
Article
in English
| MEDLINE | ID: mdl-28645941
13.
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
Clin Cancer Res
; 11(9): 3296-302, 2005 May 01.
Article
in English
| MEDLINE | ID: mdl-15867226
14.
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Clin Cancer Res
; 11(10): 3836-45, 2005 May 15.
Article
in English
| MEDLINE | ID: mdl-15897584
15.
Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
Cancer Res
; 62(14): 3950-5, 2002 Jul 15.
Article
in English
| MEDLINE | ID: mdl-12124325
16.
The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Clin Cancer Res
; 9(16 Pt 1): 6052-61, 2003 Dec 01.
Article
in English
| MEDLINE | ID: mdl-14676132
17.
Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.
Mol Cancer Ther
; 2(6): 549-55, 2003 Jun.
Article
in English
| MEDLINE | ID: mdl-12813134
18.
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Cancer Chemother Pharmacol
; 75(1): 183-9, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25417902
19.
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
J Clin Oncol
; 33(34): 4023-31, 2015 Dec 01.
Article
in English
| MEDLINE | ID: mdl-26392102
20.
Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis.
Microbes Infect
; 4(8): 773-84, 2002 Jul.
Article
in English
| MEDLINE | ID: mdl-12270724